view original post

In the last trading session, 6.77 million shares of the Iterum Therapeutics plc (NASDAQ:ITRM) were traded, and its beta was 1.21. Most recently the company’s share price was $0.46, and it changed around -$0.04 or -7.07% from the last close, which brings the market valuation of the company to $85.50M. ITRM currently trades at a discount to its 52-week high of $2.99, offering almost -550.0% off that amount. The share price’s 52-week low was $0.48, which indicates that the current value has fallen by an impressive -4.35% since then. We note from Iterum Therapeutics plc’s average daily trading volume that its 10-day average is 4.9 million shares, with the 3-month average coming to 5.57 million.

Iterum Therapeutics plc stock received a consensus recommendation rating of a Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended ITRM as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Iterum Therapeutics plc is expected to report earnings per share of $0.12 for the current quarter.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

Instantly ITRM has showed a red trend with a performance of -7.07% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5599 on Monday, 11/22/21 increased the stock’s daily price by 17.84%. The company’s shares are currently down -53.49% year-to-date, but still down -16.59% over the last five days. On the other hand, Iterum Therapeutics plc (NASDAQ:ITRM) is -11.89% down in the 30-day period. We can see from the shorts that 4.28 million shares have been sold at a short interest cover period of 0.47 day(s).

The consensus price target as assigned by Wall Street analysts is $1.00, which translates to bulls needing to increase their stock price by 54.0% from its current value. Analyst projections state that ITRM is forecast to be at a low of $1.00 and a high of $1.00. In order for the stock price to hit the forecast high, the stock would need to plunge -117.39% from its current level, while the stock would need to crash -117.39% from its current level to reach the projected low.

Iterum Therapeutics plc (ITRM) estimates and forecasts

Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain 120.00% in revenue this quarter, and will report an increase of 81.50% in the next quarter.

ITRM Dividends

Iterum Therapeutics plc’s next quarterly earnings report is expected to be released around August 04 and August 09.

Iterum Therapeutics plc (NASDAQ:ITRM)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.62% of Iterum Therapeutics plc shares, and 8.48% of them are in the hands of institutional investors. The stock currently has a share float of 8.54%. Iterum Therapeutics plc stock is held by 46 institutions, with Canaan Partners X LLC being the largest institutional investor. By Sep 29, 2021, it held 0.95% of the shares, which is about 1.73 million shares worth $0.97 million.

New Leaf Venture Partners, L.l.c., with 0.80% or 1.46 million shares worth $0.81 million as of Sep 29, 2021, holds the second largest percentage of outstanding shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

Legg Mason Global Asset Mgt Tr-QS US Small Cap Equity and Fidelity NASDAQ Composite Index ETF were the top two Mutual Funds as of Jun 29, 2021. The former held 0.38 million shares worth $0.87 million, making up 0.21% of all outstanding shares. On the other hand, Fidelity NASDAQ Composite Index ETF held roughly 96158.0 shares worth around $53694.0, which represents about 0.05% of the total shares outstanding.